FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071738192> ?p ?o ?g. }

• W2071738192 endingPage "477" @default.
• W2071738192 startingPage "477" @default.
• W2071738192 abstract "Safety of indacaterol in the treatment of patients with COPD James F Donohue1, Dave Singh2, Oliver Kornmann3, David Lawrence4, Cheryl Lassen4, Benjamin Kramer5 1University of North Carolina, Chapel Hill, NC, USA; 2University of Manchester, Medicines Evaluation Unit, Manchester, UK; 3IKF Pneumologie GmbH and Co KG, Clinical Research Centre Respiratory Diseases, Frankfurt, Germany; 4Novartis Horsham Research Centre, Horsham, UK; 5Novartis Pharmaceuticals Inc, East Hanover, New Jersey, USA Purpose: Pooled data were analyzed to evaluate the safety and tolerability of indacaterol, a once-daily inhaled long-acting ß2-agonist for chronic obstructive pulmonary disease (COPD). Patients and methods: Data were pooled from clinical studies of 3–12 months’ duration in patients with moderate-to-severe COPD receiving double-blind indacaterol 75 µg (n = 449), 150 µg (n = 2611), 300 µg (n = 1157), or 600 µg once daily (n = 547); formoterol 12 µg twice daily (n = 556); salmeterol 50 µg twice daily (n = 895); placebo (n = 2012); or tiotropium 18 µg once daily, given open label or blinded (n = 1214). Outcomes were adverse events, serious adverse events and deaths, plasma potassium, blood glucose, and QTc interval and vital signs. Results: The commonest adverse events with indacaterol were COPD worsening, nasopharyngitis, and headache; most cases were mild or moderate and incidence was generally similar to placebo and other active treatments. The risk of acute respiratory serious adverse events (leading to hospitalization, intubation, or death) was not significantly increased with any of the active treatments compared with placebo. COPD exacerbation rates (analyzed in the intent-to-treat population) were significantly reduced with all active treatments versus placebo. Hazard ratios versus placebo for major cardiovascular adverse events were <1 for all indacaterol doses. Notable values for vital signs and measures of systemic ß2-adrenoceptor activity were rare with indacaterol. The number of deaths adjusted per patient-year was lower with indacaterol (all doses combined) than with placebo (relative risk 0.21 [95% confidence interval 0.07–0.660], P = 0.008). Conclusion: Indacaterol has a good profile of safety and tolerability that is appropriate for the maintenance treatment of patients with COPD. Keywords: indacaterol, safety, tolerability, formoterol, salmeterol, tiotropium" @default.
• W2071738192 created "2016-06-24" @default.
• W2071738192 creator A5047860029 @default.
• W2071738192 creator A5048049198 @default.
• W2071738192 creator A5048294207 @default.
• W2071738192 creator A5060123928 @default.
• W2071738192 creator A5068917661 @default.
• W2071738192 creator A5082487198 @default.
• W2071738192 date "2011-09-01" @default.
• W2071738192 modified "2023-09-27" @default.
• W2071738192 title "Safety of indacaterol in the treatment of patients with COPD" @default.
• W2071738192 cites W188075496 @default.
• W2071738192 cites W1920721512 @default.
• W2071738192 cites W1966891588 @default.
• W2071738192 cites W1986085065 @default.
• W2071738192 cites W1990744788 @default.
• W2071738192 cites W2002726093 @default.
• W2071738192 cites W2004780292 @default.
• W2071738192 cites W2006193143 @default.
• W2071738192 cites W2009498514 @default.
• W2071738192 cites W2014822737 @default.
• W2071738192 cites W2016274438 @default.
• W2071738192 cites W2045274653 @default.
• W2071738192 cites W2050477739 @default.
• W2071738192 cites W2051719749 @default.
• W2071738192 cites W2052977441 @default.
• W2071738192 cites W2054329313 @default.
• W2071738192 cites W2057359869 @default.
• W2071738192 cites W2070935883 @default.
• W2071738192 cites W2072038990 @default.
• W2071738192 cites W2077389953 @default.
• W2071738192 cites W2083436606 @default.
• W2071738192 cites W2089834473 @default.
• W2071738192 cites W2096723137 @default.
• W2071738192 cites W2100277531 @default.
• W2071738192 cites W2105673902 @default.
• W2071738192 cites W2106698492 @default.
• W2071738192 cites W2111722183 @default.
• W2071738192 cites W2117079401 @default.
• W2071738192 cites W2118954823 @default.
• W2071738192 cites W2121105440 @default.
• W2071738192 cites W2124481948 @default.
• W2071738192 cites W2125373114 @default.
• W2071738192 cites W2125779455 @default.
• W2071738192 cites W2127294121 @default.
• W2071738192 cites W2130703359 @default.
• W2071738192 cites W2133343848 @default.
• W2071738192 cites W2138833643 @default.
• W2071738192 cites W2138890460 @default.
• W2071738192 cites W2139347600 @default.
• W2071738192 cites W2141034778 @default.
• W2071738192 cites W2141887601 @default.
• W2071738192 cites W2142633372 @default.
• W2071738192 cites W2142724633 @default.
• W2071738192 cites W2145152803 @default.
• W2071738192 cites W2149388258 @default.
• W2071738192 cites W2149766225 @default.
• W2071738192 cites W2149825365 @default.
• W2071738192 cites W2152263025 @default.
• W2071738192 cites W2154476916 @default.
• W2071738192 cites W2158530076 @default.
• W2071738192 cites W2159480781 @default.
• W2071738192 cites W2162627911 @default.
• W2071738192 cites W2163247562 @default.
• W2071738192 cites W2163441905 @default.
• W2071738192 cites W2166780351 @default.
• W2071738192 cites W2167941825 @default.
• W2071738192 cites W2170298115 @default.
• W2071738192 cites W2186220568 @default.
• W2071738192 cites W2317404518 @default.
• W2071738192 cites W2321545438 @default.
• W2071738192 cites W2168501375 @default.
• W2071738192 doi "https://doi.org/10.2147/copd.s23816" @default.
• W2071738192 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3186746" @default.
• W2071738192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22003293" @default.
• W2071738192 hasPublicationYear "2011" @default.
• W2071738192 type Work @default.
• W2071738192 sameAs 2071738192 @default.
• W2071738192 citedByCount "51" @default.
• W2071738192 countsByYear W20717381922012 @default.
• W2071738192 countsByYear W20717381922013 @default.
• W2071738192 countsByYear W20717381922014 @default.
• W2071738192 countsByYear W20717381922015 @default.
• W2071738192 countsByYear W20717381922017 @default.
• W2071738192 countsByYear W20717381922018 @default.
• W2071738192 countsByYear W20717381922019 @default.
• W2071738192 countsByYear W20717381922020 @default.
• W2071738192 countsByYear W20717381922021 @default.
• W2071738192 countsByYear W20717381922022 @default.
• W2071738192 crossrefType "journal-article" @default.
• W2071738192 hasAuthorship W2071738192A5047860029 @default.
• W2071738192 hasAuthorship W2071738192A5048049198 @default.
• W2071738192 hasAuthorship W2071738192A5048294207 @default.
• W2071738192 hasAuthorship W2071738192A5060123928 @default.
• W2071738192 hasAuthorship W2071738192A5068917661 @default.
• W2071738192 hasAuthorship W2071738192A5082487198 @default.
• W2071738192 hasBestOaLocation W20717381921 @default.
• W2071738192 hasConcept C126322002 @default.

• next